Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
11-DOC11-deoxycorticosterone
AAAldosterone antagonist
ABPMAmbulatory blood pressure monitoring
ACCAmerican College of Cardiology
ACC.25American College of Cardiology's Annual Scientific Session & Expo 2025
ACEAngiotensin-converting enzyme
ACEiAngiotensin-converting enzyme inhibitor
ACTHAdrenocorticotropic hormone
ADEsAdverse drug events
AE, AEsAdverse event
AESIsAdverse events of special interest
AFAtrial fibrillation
AHAAmerican Heart Association
AHFSAmerican Hospital Formulary Service
AHIApnea-hypopnea index
aHRAdjusted hazard ratio
AHT, AHTsAntihypertensive; antihypertensive treatments
AKIAcute kidney injury
ANCAAnti-neutrophil cytoplasmic antibody
ANPAtrial natriuretic peptide
AOBPAutomated office blood pressure
AODBPAutomated office diastolic blood pressure
aORAdjusted odds ratio
AOSBPAutomated office systolic blood pressure
ARB, ARBsAngiotensin II receptor blocker
aRHTApparent resistant hypertension
ARICAtherosclerosis Risk in Communities study
ARRAldosterone-renin ratio
ASBPAmbulatory systolic blood pressure
ASCVDAtherosclerotic cardiovascular disease
ASI, ASIsAldosterone synthase inhibitor
aTRHApparent treatment-resistant hypertension
AUC, AUCsArea under the concentration-time curve
AUC0–∞Area under the concentration-time curve from time 0 to infinity
AUC0–24Area under the concentration-time curve from 0 to 24 hours
AVSAdrenal vein sampling
BAXBaxdrostat
BB, BBsBeta-blocker
BEBOStichting Beoordeling Ethiek Biomedisch Onderzoek (Foundation for the Review of Ethics in Biomedical Research, Assen, Netherlands)
BI 690517Boehringer Ingelheim development code for vicadrostat
BIDTwice daily
BiPAPBilevel positive airway pressure
BMIBody mass index
BNPBrain natriuretic peptide
BP, BPsBlood pressure
BPC-EBlood Pressure Control for Patients With Hypertension (HEDIS measure)
BPLTTCBlood Pressure Lowering Treatment Trialists' Collaboration
C-LIFELifestyle modification program (dietary counseling, behavioral weight management, and exercise) in the TRIUMPH trial
C5ResearchCleveland Clinic Coordinating Center for Clinical Research
CADCoronary artery disease
CARDIACoronary Artery Risk Development in Young Adults study
CASChemical Abstracts Service
CaTRHControlled apparent treatment-resistant hypertension
CBPControlling High Blood Pressure (HEDIS measure)
CCB, CCBsCalcium channel blocker
CDCCenters for Disease Control and Prevention
CEDCoverage with Evidence Development
CEPACComparative Effectiveness Public Advisory Council
CESTCentral European Summer Time
CHDCoronary heart disease
CHFCongestive heart failure
CHMPCommittee for Medicinal Products for Human Use (European Medicines Agency)
CI, CIsConfidence interval
CKDChronic kidney disease
CKD-EPIChronic Kidney Disease Epidemiology Collaboration
CLConfidence limit
CLADCensored least absolute deviations
CLICKChlorthalidone in Chronic Kidney Disease trial
CLRRenal clearance
CmaxMaximum observed plasma concentration
CMSCenters for Medicare & Medicaid Services
CORClass of recommendation
CPAPContinuous positive airway pressure
CPTCurrent Procedural Terminology
cRHControlled resistant hypertension
CrICredible interval
CRMNCost-related medication nonadherence
CRNCost-related nonadherence
CROContract research organization
CTCentral Time; computed tomography
CUAsCost-utility analyses
CVCardiovascular
CVACerebrovascular accident
CVDCardiovascular disease
CVOTCardiovascular outcomes trial
CYPCytochrome P450
CYP11B1, hCYP11B111β-hydroxylase (cytochrome P450 11B1); human CYP11B1
CYP11B2, hCYP11B2Aldosterone synthase (cytochrome P450 11B2); human CYP11B2
CYP3A, CYP3A4Cytochrome P450 3A, cytochrome P450 3A4
DASHDietary Approaches to Stop Hypertension
DBDouble-blind
DBPDiastolic blood pressure
DMCData Monitoring Committee
DRCDirect renin concentration
DRGDiagnosis-related group
ECG, ECGsElectrocardiogram
EDEmergency department
eGFR, eGFRsEstimated glomerular filtration rate
EMRElectronic medical record
ENaCEpithelial sodium channel
EoSEnd of study
EoTEnd of treatment
EPLEplerenone
EQ-5DEuroQol 5-Dimension questionnaire
EQ-5D-5LEuroQol 5-Dimension 5-Level questionnaire
ERA, ERAsEndothelin receptor antagonist
ESCEuropean Society of Cardiology
ESHEuropean Society of Hypertension
ESKDEnd-stage kidney disease
ESRDEnd-stage renal disease
ESSEpworth Sleepiness Scale
ET, ET-1Endothelin, endothelin-1
ETA, ETBEndothelin receptor type A, endothelin receptor type B
EtDEvidence to Decision
EUEuropean Union
EudraCTEuropean Union Drug Regulating Authorities Clinical Trials Database
evLY, evLYsEqual value life year
FDAU.S. Food and Drug Administration
FEC, FECsFree-equivalent combination
FOSQ, FOSQ-10Functional Outcomes of Sleep Questionnaire; Functional Outcomes of Sleep Questionnaire-10
GDMTGuideline-directed medical therapy
GDPGross domestic product; guideline development panel
GFRGlomerular filtration rate
GLP-1Glucagon-like peptide-1
GPERG protein-coupled estrogen receptor
GPR30G protein-coupled receptor 30
GRADEGrading of Recommendations Assessment, Development and Evaluation
HbA1c, HbA1CGlycosylated hemoglobin
HBPHigh blood pressure
HBPBHealth Benefit Price Benchmark
HBPMHome blood pressure monitoring
HCLHydrochloride
HCTZHydrochlorothiazide
HEDISHealthcare Effectiveness Data and Information Set
hERGHuman ether-a-go-go-related gene (cardiac potassium channel)
HFHeart failure
HR, HRsHazard ratio; heart rate
HrQoL, HRQoLHealth-related quality of life
HTHypertension
HTAHealth technology assessment
HTNHypertension
ICIntercurrent events
IC50Half-maximal inhibitory concentration
ICD-9International Classification of Diseases, Ninth Revision
ICEIntercurrent event
ICER, ICERsInstitute for Clinical and Economic Review; incremental cost-effectiveness ratio
ICFInformed consent form
ICHIntracerebral hemorrhage
IDIdentification
IHDIschemic heart disease
IHEIschemic heart event
INNInternational Nonproprietary Name
IQRInterquartile range
ISPORISPOR, The Professional Society for Health Economics and Outcomes Research
LORLorundrostat
LPLorundrostat-placebo (treatment sequence)
LSLeast squares
LSM, LSmeansLeast squares mean
LY, LYsLife year
MAMedicare Advantage
MACEMajor adverse cardiovascular events
MAD, MADsMultiple ascending dose
MARMissing at random
MATE, MATE1Multidrug and toxin extrusion; multidrug and toxin extrusion 1
MCSMental component summary
MDMean difference
MDTMultidisciplinary team
MEPSMedical Expenditure Panel Survey
MIMyocardial infarction
MLS-101Mineralys Therapeutics development code for lorundrostat
MNARMissing not at random
MRMineralocorticoid receptor
MRA, MRAsMineralocorticoid receptor antagonist
MT-4129Mitsubishi Tanabe Pharma development code for lorundrostat
NANot applicable
NADACNational Average Drug Acquisition Cost
NDANew Drug Application
NDCNational Drug Code
NEJMThe New England Journal of Medicine
NHANESNational Health and Nutrition Examination Survey
NMANetwork meta-analysis
non-RHNonresistant hypertension
NPLBNo Patient Left Behind
NSNot significant
NSAIDsNonsteroidal anti-inflammatory drugs
NT-proBNPN-terminal pro-B-type natriuretic peptide
OLEOpen-label extension
OROdds ratio
OSAObstructive sleep apnea
P/IPromising but Inconclusive (ICER evidence rating)
PAPrimary aldosteronism
PACPlasma aldosterone concentration
PAPPositive airway pressure
PATHWAY-2Prevention And Treatment of Hypertension With Algorithm-based therapY 2 trial
PBOPlacebo
PCSPhysical component summary
PDPharmacodynamics
PDUFAPrescription Drug User Fee Act
PIPrincipal investigator
PIEPre-approval information exchange
PKPharmacokinetics
PLPlacebo-lorundrostat (treatment sequence)
poOrally
PRPR interval (electrocardiogram)
PRAPlasma renin activity; Pharmaceutical Research Associates
PROMISPatient-Reported Outcomes Measurement Information System
PROMIS-SDPatient-Reported Outcomes Measurement Information System - Sleep Disturbance
PSPPatient support program
QALY, QALYsQuality-adjusted life year
QDOnce daily
QRSQRS complex (electrocardiogram)
QTQT interval (electrocardiogram)
QTcHeart-rate corrected QT interval
QTcFQT interval corrected for heart rate by Fridericia's method
RAASRenin-angiotensin-aldosterone system
RALESRandomized Aldactone Evaluation Study
RASRenin-angiotensin system
RCT, RCTsRandomized controlled trial
RDNRenal denervation
REGARDSReasons for Geographic and Racial Differences in Stroke study
ReHOTResistant Hypertension Optimal Treatment trial
REMSRisk Evaluation and Mitigation Strategy
RFRadiofrequency
rfRDNRadiofrequency renal denervation
RHResistant hypertension
RHTResistant hypertension
rHTN, RHTNResistant hypertension
RRRisk ratio; relative risk
RTSMRandomization and trial supply management
RTWRandomized treatment withdrawal
SAD, SADsSingle ascending dose
SAEsSerious adverse events
SAPStatistical analysis plan
SBSingle-blind
SBPSystolic blood pressure
SDStandard deviation
SEStandard error
seated-SBPSeated office systolic blood pressure
SECU.S. Securities and Exchange Commission
SEMStandard error of the mean
SEPAStandardized education and physician advice
SF-12, SF-3612-item and 36-item Short Form Health Surveys
SF-6DShort Form 6-Dimension utility index
SGLT2Sodium-glucose cotransporter 2
SGLT2iSodium-glucose cotransporter 2 inhibitor
siRNASmall interfering ribonucleic acid
SiSBPSitting systolic blood pressure
SMBPSelf-measured blood pressure
sNDASupplemental New Drug Application
SoCStandard of care
SPC, SPCsSingle-pill combination
SPIRSpironolactone
SRISleep-Related Impairment (PROMIS)
t1/2Apparent terminal elimination half-life
T2DMType 2 diabetes mellitus
TBCTeam-based care
TDMTherapeutic drug monitoring
TEAE, TEAEsTreatment-emergent adverse event
TmaxTime to maximum observed plasma concentration
TRHTreatment-resistant hypertension
trHTNTreatment-resistant hypertension
TRIUMPHTreating Resistant Hypertension Using Lifestyle Modification to Promote Health trial
UACRUrinary albumin-to-creatinine ratio
UAldoUrinary aldosterone
uAOBPUnattended automated office blood pressure
UaTRHUncontrolled apparent treatment-resistant hypertension
ucHTNUncontrolled hypertension
UCortUrinary cortisol
uHTNUncontrolled hypertension
UKUnited Kingdom; urinary potassium
UNaUrinary sodium
uRDNUltrasound renal denervation
uRHUncontrolled resistant hypertension
USUnited States
USAUnited States of America
USPSTFU.S. Preventive Services Task Force
WACWholesale acquisition cost
WHOWorld Health Organization
WTPWillingness to pay
ΔQTcFChange from baseline in QTcF
ΔΔQTcFPlacebo-corrected change from baseline in QTcF